MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

chất chủ vận PPAR

  • Home
  • chất chủ vận PPAR
Saroglitazar在原发性胆汁性胆管炎中的应用：来自2b/3期自适应随机试验的启示
Posted inClinical Updates Gastroenterology

Saroglitazar in Primary Biliary Cholangitis: Insights from a Phase 2b/3 Adaptive Randomized Trial

Posted by By MedXY 11/02/2026
Saroglitazar, a dual PPAR α/γ agonist, demonstrated significant biochemical improvement and ALP normalization in primary biliary cholangitis patients refractory or intolerant to UDCA, with favorable safety over 52 weeks in a phase 2b/3 trial.
Read More
  • Saroglitazar in Primary Biliary Cholangitis: Insights from a Phase 2b/3 Adaptive Randomized Trial
  • eHealth-Guided Exercise Enhances Peak Oxygen Uptake and Quality of Life Post-COVID-19: A Randomized Controlled Trial
  • Five-Year Outcomes of Arthroscopic Bankart Repair in Young Athletes With Minimal Glenoid Bone Loss: Recurrence, Return to Sport, and Risk Factors
  • Age-Related Differences Influence Outcomes of Long-Term Multimodal Stroke Intervention: Insights from the LAST-long Trial
  • Linking Oral Health to Liver Cancer Risk: Insights from a Nationwide Swedish Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top